RAD51 and ovarian carcinoma: A sequential combination of crizotinib and a PARPi resulted in activation of ATM/CHK2 and inhibition of c-Met pathways, contributing to a decrease in RAD51 levels and induced apoptotic cell death in ovarian cancer cell lines [70].